Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this
research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given
to subjects without having too many side effects.
The Phase II portion of this study is to see what side effects are seen with medication after
transplant.
Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown
to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL) and
Non-Hodgkin's Lymphoma (NHL).
Inotuzumab ozogamicin is considered experimental in this study.